Ascendis Pharma A/S (ASND)

$93.44

-0.76 (-0.81%)
Rating:
Recommendation:
Neutral
Symbol ASND
Price $93.44
Beta 0.863
Volume Avg. 0.52M
Market Cap 5.214B
Shares () -
52 Week Range 61.579-178.71
1y Target Est -
DCF Unlevered ASND DCF ->
DCF Levered ASND LDCF ->
ROE -55.14% Strong Sell
ROA -32.40% Strong Sell
Operating Margin -
Debt / Equity 104.70% Buy
P/E -
P/B 6.70 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ASND news


Mr. Jan Moeller Mikkelsen
Healthcare
Biotechnology
NASDAQ Global Select

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.